← boothcheck

Is MPT overvalued?

boothcheck doesn't label MPT overvalued or undervalued and publishes no house fair value, target price, or buy/sell rating. Individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet. The report narrative was composed 2026-06-27. The more the price assumes beyond what MEDICAL PROPERTIES TRUST, INC. has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.

Derived from MEDICAL PROPERTIES TRUST, INC.'s SEC EDGAR filings via a reverse-DCF inversion. Last analyzed June 27, 2026.

Implied growth
For about
Held margin (input)
Margin today
Price vs asset value0.68x
Price vs earnings power1.12x
Price vs peer multiples0.90x
Price vs forward growth1.10x
Read the full MPT report →
Get boothcheck's read on what MPT's price is betting on, in your inbox when it moves. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.